| "Due to its low efficacy, 40% in the treatment of chronic hepatitis B and 10-20% in the treatment of chronic hepatitis C, and to its adverse events, in some cases severe, new antiviric molecules are being investigated." | ( Córdoba Cortijo, J; López Viedma, B; Olaso Peiró, V, 1998) |
| "Two patients were treated for chronic hepatitis B with lamivudine and subsequently underwent renal transplantation." | ( Han, DJ; Jung, YO; Lee, YS; Park, JS; Park, SK; Yang, WS, 1998) |
| "A consensus meeting on the treatment of chronic hepatitis B infection was conducted in Hong Kong, in August 1997." | ( Carman, WF; Lam, SK; Lau, GK; Locarnini, SA; Lu, ZM; Okuda, K; Williams, R, 1999) |
| "It has achieved a milestone in the treatment of chronic hepatitis B and is now commercially available in many countries." | ( Leung, N, 2000) |
| "Standard treatment of chronic hepatitis B virus infection includes the use of interferon-a and antiviral nucleoside analogues, alternatively." | ( Gerken, G, 2000) |
| "Immunomodulatory approaches to treatment of chronic hepatitis B are conceptually attractive, but newer agents used to date (thymalfasin, interleukin-12, therapeutic vaccines) have not demonstrated sufficient efficacy for widespread use." | ( Farrell, GC, 2000) |
| "Larger studies with lamivudine treatment in chronic hepatitis B were mainly performed in North America and Asia." | ( Berg, T; Kallinowski, B; Löhr, HF; Müller, R; Teuber, G; Zeuzem, S, 2001) |
| "Our study shows that lamivudine treatment in chronic hepatitis B can restore CTL reactivity, making CTL susceptible to exogenous stimulation." | ( Bertoletti, A; Boehme, R; Boni, C; Cavalli, A; Cavallo, C; Ferrari, C; Fiaccadori, F; Ogg, GS; Panebianco, R; Penna, A; Pilli, M; Urbani, S, 2001) |
| "In patients treated for chronic hepatitis B infection the cumulative incidence of viral resistance reaches over 50% after 3 years." | ( Fischer, KP; Gutfreund, KS; Tyrrell, DL, 2001) |
| "In the interferon (IFN) treatment of chronic hepatitis B, there is no accepted definition of virological response as measured by highly sensitive HBV DNA assays." | ( Hannoun, C; Horal, P; Krogsgaard, K; Lindh, M, 2001) |
| "For the treatment of chronic hepatitis B (CHB) two drugs have been licensed world-wide: interferon-alpha (IFN) and lamivudine." | ( de Man, RA; Janssen, HL; Niesters, HG; Schalm, SW; van Nunen, AB; Wolters, LM, 2001) |
| "Trials of thymosin treatment in chronic hepatitis B virus infection have been small and the results have been inconsistent." | ( Chan, HL; Sung, JJ; Tam, W; Tang, JL, 2001) |
| "placebo (or usual care) in the treatment of chronic hepatitis B virus infection were identified through MEDLINE, EMBASE and the Cochrane Register of Clinical Trials." | ( Chan, HL; Sung, JJ; Tam, W; Tang, JL, 2001) |
| "As to anti-viral treatment of chronic hepatitis B, the triplex superimposed treatment had better efficacy than lamivudine alone." | ( Du, KF; Liu, H; Lu, ZG; Wu, L; Xue, P, 2001) |
| "Lamivudine is registered for the treatment of chronic hepatitis B and can be used as a prophylactic prior to chemotherapy or to treat an exacerbation of the hepatitis." | ( de Man, RA; Doorduijn, JK; Janssen, HL; Niesters, HG; Schalm, SW; van der Eijk, AA, 2002) |
| "Currently available treatments for chronic hepatitis B (interferon [IFN]-alpha and lamivudine [3TC]) have limited long-term utility because of side effects or of the development of resistance." | ( Aberg, JA; Crippin, J; Kessels, L; Lisker-Melman, M; Powderly, WG; Ristig, MB; Tebas, P, 2002) |
| "Combination treatment of chronic hepatitis B with prednisone, IFN-alpha, and FAM seems to be a safe and effective treatment option for children surviving pediatric malignancy." | ( Benesch, M; Deutsch, J; Dornbusch, HJ; Kerbl, R; Kessler, HH; Lackner, H; Moser, A; Schwinger, W; Sovinz, P; Urban, C, 2002) |
| "We aimed to treat patients with chronic hepatitis B on long-term treatment with lamivudine who developed lamivudine-resistant hepatitis B virus (HBV) mutants along with clinical relapses." | ( Akuta, N; Arase, Y; Ikeda, K; Kobayashi, M; Kumada, H; Miyakawa, Y; Saitoh, S; Someya, T; Suzuki, F; Suzuki, Y; Tsubota, A, 2002) |
| "Oxymatrine is effective in treating chronic hepatitis B." | ( Chen, YX; Jiang, JH; Mao, BY, 2002) |
| "Lamivudine treatment in chronic hepatitis B leads to the reconstitution of virus-specific T cells in the circulation, but it is not clear whether this is the preferential result of T cell efflux from the liver or lymph nodes." | ( Behboudi, S; Bertoletti, A; Burroughs, AK; Dusheiko, GM; Gotto, J; Malacarne, F; Reignat, S; Webster, GJ; Williams, R, 2003) |
| "The results showed that after one year treatment of chronic hepatitis B with Lamivudine, the recovery rate of ALT was 90." | ( Chen, N; Cui, X; Li, X; Ru, H; Tang, Z; Wen, X; Xie, H; Zeng, W, 2002) |
| "Current therapies for the treatment of chronic hepatitis B virus (HBV) infection do not eliminate viral replication once therapy is stopped, resulting in a rapid rebound of viremia in a majority of patients." | ( Barcena Marugan, R; Cid Gomez, L; Lopez Serrano, P, 2003) |
| "In the treatment of chronic hepatitis B (CHB) with lamivudine, adequate duration of the therapy remains to be determined." | ( Choi, MH; Chung, YH; Jang, MK; Kim, JA; Lee, HC; Lee, YS; Park, NH; Ryu, SH; Shin, JW; Suh, DJ, 2003) |
| "It is indicated for the treatment of chronic hepatitis B in adults." | ( Dando, T; Plosker, G, 2003) |
| "During treatment of chronic hepatitis B with lamivudine, changes in the level of hepatitis B virus (HBV) DNA were investigated using a real-time polymerase chain reaction (PCR) method with a detection limit of 1." | ( Hino, T; Hisamochi, A; Ide, T; Koga, Y; Kumashiro, R; Kuwahara, R; Murashima, S; Ogata, K; Sata, M; Tanaka, E; Tanaka, K, 2003) |
| "Lamivudine is used for the treatment of chronic hepatitis B (CH-B), and exhibits excellent antiviral activity." | ( Akuta, N; Arase, Y; Hosaka, T; Ikeda, K; Kobayashi, M; Kumada, H; Matsuda, M; Saitoh, S; Satoh, J; Someya, T; Suzuki, F; Suzuki, Y; Takagi, K; Tsubota, A, 2004) |
| "HJD is effective for treating chronic hepatitis B, and its effect seems to relate with the improvement of the TCRVbeta7 expression of chronic hepatitis B patients, thus activating T cells and eliminating HBV." | ( Chen, ZX; Huang, BJ; Lao, SX; Zhang, SJ, 2004) |
| "Lamivudine was approved for the treatment of chronic hepatitis B in China in 1999; however the long-term result has not yet been reported in detail." | ( Cui, ZY; Wang, BE; Yao, GB; Yao, JL; Zeng, MD, 2004) |
| "Currently approved treatments for chronic hepatitis B are limited by low rates of sustained response, side effects, or drug resistance." | ( Lok, AS, 2004) |
| "Current therapies available for the treatment of chronic hepatitis B are limited in their ability to result in a cure." | ( Blum, MR; Bronowicki, JP; Conway, B; Lau, GK; Lee, HS; Marcellin, P; Mommeja-Marin, H; Mondou, E; Rousseau, F; Sacks, SL; Sereni, D; Snow, A; Sorbel, J; Trepo, C; Yoo, BC, 2004) |
| "Diagnosis and treatment of chronic hepatitis B serves prevention of liver cirrhosis and hepatocellular carcinoma as well as elimination of the sources of further infections." | ( Telegdy, L, 2004) |
| "The primary aim in the treatment of chronic hepatitis B is to induce sustained disease remission and prevent serious complications like liver failure and/or hepatocellular carcinoma." | ( Janssen, HL; Sprengers, D, 2005) |
| "A new nucleoside analog for treating chronic hepatitis B infection." | ( , 2005) |
| "Adefovir dipivoxil is indicated for the treatment of chronic hepatitis B in adults with evidence of active viral replication and either evidence of persistent elevations in serum aminotransferases (alanine [ALT] or aspartate [AST]) or histologically active disease." | ( Baker, DE, 2005) |
| "The efficacy of lamivudine re-treatment in chronic hepatitis B (CHB) patients who relapse after HBeAg seroconversion with lamivudine has not been investigated." | ( Bang, SJ; Jeong, ID; Joo, KR; Kim, DH; Park, JH; Park, NH; Shin, JW, 2005) |
| "Although lamivudine is effective for treatment of chronic hepatitis B (HBV) infection, its potential therapeutic impact on HBV-related membranous nephropathy (MN) in adults has not been characterized." | ( Chan, KW; Ho, YW; Kung, NN; Lai, FM; Lai, KN; Leung, JC; Lui, YH; Tang, CS; Tang, S, 2005) |
| "Adefovir dipivoxil is safe for the treatment of chronic hepatitis B in patients with varying degrees of renal dysfunction and lamivudine-resistant HBV and results in biochemical and virological efficacy similar to that reported in the general population." | ( Brosgart, C; Chaix, ML; Currie, G; Fontaine, H; Morales, E; Nalpas, B; Pol, S; Serpaggi, J; Vallet-Pichard, A; Varaut, A; Verkarre, V, 2005) |
| "Recent guidelines for the treatment of chronic hepatitis B based on the accumulated knowledge on the disesase pathogenesis and treatment outcome are presented." | ( Morović, M, 2005) |
| "HJT is effective in treating chronic hepatitis B." | ( Chen, ZX; Gu, YL; Guan, SH; Hu, HT; Lao, SX; Zhang, CY; Zhang, SJ, 2005) |
| "Current treatments for chronic hepatitis B virus (HBV) infection include the use of interferon-alpha and of nucleoside analogs lamivudine, adefovir and entecavir." | ( Ang, TH; Bai, J; Chen, Y; Kong, KH; Lam, Y; Li, Y; Lim, SG; Tan, TM, 2006) |
| "There are 3 drugs registered to treatment of chronic hepatitis B: interferon, lamivudine and adefovir." | ( Halota, W; Pawłowska, M, 2006) |
| "Registered treatment for chronic hepatitis B currently consists of (pegylated) interferon, lamivudine and adefovir, while entecavir is expected to be licensed in the short term." | ( Buster, EH; Janssen, HL, 2006) |
| "Sequential treatment of chronic hepatitis B with lamivudine and interferon-alpha monotherapies is as effective as lamivudine-alone treatment in Chinese patients." | ( Han, B; Jin, LJ; Shi, M; Wang, RS; Xu, YP; Yang, ZJ; Zhang, H; Zhang, Y; Zhu, YF, 2006) |
| "Lamivudine is widely used for the treatment of chronic hepatitis B infection because of it's remarkable antiviral efficacy and safety." | ( Baik, du S; Kim, BH; Kim, HJ; Kim, SB; Seo, PJ; Shin, JE; Song, IH; Yun, SY, 2006) |
| "Standard treatments for chronic hepatitis B (CHB) include interferon-alpha (IFN-alpha) and lamivudine (LAM), but these are associated with adverse effects and viral resistance, respectively." | ( Davidson, P; Jones, J; Price, A; Shepherd, J; Takeda, A, 2007) |
| "The results suggest that antioxidant treatment for chronic hepatitis B patients may help improve the effect of anti-virus therapy." | ( Fan, YC; Han, LY; Hou, YD; Li, XH; Wang, HM; Wang, K; Wang, LY, 2007) |
| "Six drugs have been approved for the treatment of chronic hepatitis B: interferon-alpha(2b), pegylated interferon-alpha(2a), lamivudine, adefovir, entecavir and telbivudine." | ( Ruiz-Sancho, A; Sheldon, J; Soriano, V, 2007) |
| "Peginterferon alpha-2a (40 kDa), a new treatment for chronic hepatitis B, produces seroconversion within 48 weeks in approximately 32% of HBeAg-positive patients." | ( Aledort, JE; Dusheiko, GM; Jacobs, M; Lewis, G; Patel, KK; Sullivan, SD; Veenstra, DL, 2007) |
| "We analyzed 49 LAM-treated chronic hepatitis B patients infected with hepatitis B virus (HBV) genotype C." | ( Fukai, K; Imazeki, F; Kurihara, T; Mikata, R; Yokosuka, O; Zhang, KY, 2007) |
| "Lamivudine is used for the treatment of chronic hepatitis B patients." | ( Aghakhani, A; Banifazl, M; Gachkar, L; Keyvani, H; Ramezani, A; Roshan, MR; Velayati, AA, 2008) |
| "Long-term effects of lamivudine treatment on chronic hepatitis B patients without advanced disease remain unknown." | ( Chow, DH; Fung, J; Lai, CL; Ngai, VW; Seto, WK; Tsui, K; Wong, BC; Wong, DK; Yuen, JC; Yuen, MF, 2007) |
| "Adefovir dipivoxil (ADV) is a licensed treatment for chronic hepatitis B in adults." | ( Dhawan, A; Frederick, D; Kelly, D; Mizerski, J; Sokal, EM; Wirth, S, 2008) |
| "The ultimate goal of treatment for chronic hepatitis B (CHB) is to prevent hepatocellular carcinoma (HCC)." | ( Hann, HW, 2008) |
| "Entecavir (ETV) was developed for the treatment of chronic hepatitis B virus (HBV) infection and is globally approved for that indication." | ( Colonno, R; Dicker, I; Fan, L; Gali, V; Higley, H; Krystal, M; Lin, PF; Nowicka-Sans, B; Parkin, N; Tenney, D; Terry, B; Wang, C; Zhang, S, 2008) |
| "To review the current treatment of chronic hepatitis B, with a focus on diagnosis and management of resistance and active management of suboptimal responses." | ( Ayoub, WS; Keeffe, EB, 2008) |
| "Among the six drugs licensed for the treatment of chronic hepatitis B in the US, the preferred agents in 2008 will include entecavir, peginterferon alfa-2a, possibly telbivudine, and tenofovir following licensure." | ( Ayoub, WS; Keeffe, EB, 2008) |
| "The main goal for treatment of chronic hepatitis B is to prevent complications such as liver cirrhosis or hepatocellular carcinoma." | ( Bläckberg, J; Duberg, AS; Fischler, B; Friman, S; Karlström, O; Lindh, M; Norkrans, G; Reichard, O; Sangfeldt, P; Söderström, A; Sönnerborg, A; Uhnoo, I; Weiland, O; Wejstål, R; Wiström, J, 2008) |
| "To study the efficacy of lamivudine treatment in chronic hepatitis B patients affected by structures of HBV P-genes." | ( Jiang, JJ; Wang, YP; Yan, YS, 2008) |
| "Of currently available drugs for the treatment of chronic hepatitis B, PEG-IFN seems to result in the highest rate of off-treatment sustained response after a 1-year course of therapy." | ( Buster, EH; Janssen, HL; Schalm, SW, 2008) |
| "To explore the strategy for the treatment of chronic hepatitis B with YMDD mutation." | ( Dai, YX; Ding, H; Hu, TH; Huang, LH; Jiang, XH; Jiang, YM; Qiu, YW; Zhou, M, 2009) |
| "Diagnosis and treatment of chronic hepatitis B (CHB) have improved in recent years with introduction of new oral antiviral drugs." | ( Buti, M; Córdoba, J; Esteban, R; García-Martínez, R; Les, I; Quintana, M, 2009) |
| "The initial treatment for chronic hepatitis B was interferon." | ( Kao, JH; Lim, SG; Mohammed, R; Yuen, MF, 2009) |
| "In adefovir (ADV) treated chronic hepatitis B patients carrying rtA181T/rtA181V mutations, overlap with surface gene mutations such as sW172stop/sL173F has been reported." | ( Bak, YT; Byun, KS; Joo, MK; Jung, YK; Kim, JH; Kim, JS; Park, JJ; Yeon, JE; Yim, HJ, 2010) |
| "Since its approval for the treatment of chronic hepatitis B in 1998, lamivudine (LAM) has been used extensively throughout the world, because of its relatively low costs and favourable tolerability." | ( Marcellin, P; Piratvisuth, T; Sung, J, 2010) |
| "Clevudine has been approved for the treatment of chronic hepatitis B (CHB) in South Korea." | ( Hwang, JH; Jang, JH; Jeong, SH; Kim, HS; Kim, JW; Kim, N; Lee, DH; Lee, SH; Myung, HJ; Park, YS, 2011) |
| "Such is the case for antivirals used to treat chronic hepatitis B." | ( Tenney, DJ, 2010) |
| "Current agents used in the treatment of chronic hepatitis B (CHB) can be classified into interferons-α (IFN-α: standard or pegylated) and nucleos(t)ide analogues (NUCs)." | ( Papatheodoridis, GV, 2011) |
| "Major progress in the treatment of chronic hepatitis B (CHB) has been made during the last decade with the development of antivirals that inhibit viral polymerase activity." | ( Zoulim, F, 2011) |
| "Adefovir dipivoxil is commonly used for treatment of chronic hepatitis B." | ( Dong, GF; Li, L; Xie, YS; Zhang, X, 2011) |
| "Entecavir is an effective treatment for chronic hepatitis B." | ( Bonet, L; Buti, M; Diago, M; García-Samaniego, J; Morillas, RM; Palau, A; Pérez, J; Prieto, M; Rodríguez, M; Solà, R; Testillano, M, 2012) |
| "The effectiveness of antiviral treatments of chronic hepatitis B has been poorly studied in Brazil." | ( Fernandes, CA; Gomes, Sde A; Mello, FC, 2012) |
| "ETV is effective in treating chronic hepatitis B in RTRs." | ( Chang, KC; Chen, TC; Chen, YT; Chien, YS; Chiu, KW; Hu, TH; Lin, MT; Tsai, MC, 2012) |
| "There are five approved drugs for the treatment of chronic hepatitis B(lamivudine, adefovir dipivoxil [ADV], entecavir [ETV], as well as pegylated and standard interferon) in Japan." | ( Suzuki, F, 2012) |
| "In the first year of treatment for chronic hepatitis B, virologic response and tolerability did not differ significantly between tenofovir and entecavir." | ( Akin, MS; Doğan, ÜB; Gümürdülü, Y; Kara, B; Soylu, A, 2012) |
| "New insights into the treatment of chronic hepatitis B with relevance for clinical practice have been adopted in these concise, revised guidelines." | ( Baak, BC; Bakker, CM; Beuers, UH; Brouwer, JT; Buster, EH; Drenth, JP; Honkoop, P; Janssen, HL; Kerbert-Dreteler, MJ; Koek, GH; Tan, AC; van der Spek, BW; van Erpecum, KJ; van Hoek, B; van Nieuwkerk, KM; van Soest, H; Vrolijk, JM, 2012) |
| "Currently available antiviral treatment for chronic hepatitis B virus infection can be divided into two classes of therapeutic agents: nucleos(t)ide analogues (NAs) and interferon (IFN)." | ( Enomoto, M; Kawada, N; Nishiguchi, S; Tamori, A, 2013) |
| "The ideal approach to treat chronic hepatitis B remains controversial." | ( Hagiwara, S; Inoue, T; Inuzuka, T; Kudo, M; Matsumoto, A; Matsuo, H; Nishida, N; Osaki, Y; Sakurai, T; Tanaka, E; Ueshima, K; Yada, N, 2013) |
| "Should treatment of chronic hepatitis B virus infection be necessary during pregnancy, tenofovir, listed by the FDA as pregnancy category B drug, is to be preferred." | ( Horváth, G, 2013) |
| "One major challenge in the treatment of chronic hepatitis B is to maintain long-term viral suppression without promoting the selection of drug-resistant mutations." | ( Borroto-Esoda, K; Corsa, A; Flaherty, J; Kitrinos, KM; Liu, Y; Marcellin, P; Miller, MD; Snow-Lampart, A, 2014) |
| "The efficacy of entecavir (ETV) treatment in chronic hepatitis B (CHB) patients who were exposed to lamivudine (LAM) but had no detectable LAM resistance (LAM-R) is not well evaluated." | ( Cho, Y; Cho, YY; Choi, WM; Kim, YJ; Lee, DH; Lee, HS; Lee, JH; Lee, M; Lee, YB; Yoo, JJ; Yoon, JH; Yu, SJ, 2014) |
| "Entecavir (ETV) is effective in the treatment of chronic hepatitis B virus (HBV) infections, even in patients with underlying cirrhosis." | ( Byun, KS; Hyun, JJ; Kang, S; Kim, HR; Kim, JH; Kim, SY; Koo, JS; Lee, SW; Seo, YS; Suh, SJ; Um, SH; Yeon, JE; Yim, HJ, 2015) |
| "Five nucleos(t)ide analogs are used to treat chronic hepatitis B." | ( Shan, C; Wu, P; Yin, GQ, 2014) |
| "Current agents for the treatment of chronic hepatitis B (CHB) can be classified into interferon-α (standard or pegylated) (IFN) and nucleos(t)ide analogues (NAs)." | ( Papatheodoridis, GV; Vlachogiannakos, J, 2015) |
| "Currently available antiviral treatment for chronic hepatitis B can be divided into two classes of therapeutic agents: pegylated interferon alpha (PEG-IFN) and nucleos(t)ide analogues (NAs)." | ( Dandri, M; Petersen, J, 2015) |
| "Of the 199 treatment-naive chronic hepatitis B patients, 141 (70." | ( Aktuğ Demir, N; Kölgelier, S; Özçimen, S; Sümer, Ş, 2014) |
| "The goal of treatment for chronic hepatitis B (CHB) is now to improve quality of life and to prevent the poor outcomes of the disease rather than to eliminate the virus from the body." | ( Abdurakhmanov, DT; Otrashevskaya, AV, 2014) |
| "Entecavir (ETV) is approved for the treatment of chronic hepatitis B virus (HBV) infections, but the virus can acquire resistance to the drug." | ( Hayashi, S; Iio, E; Isogawa, M; Karino, Y; Matsui, T; Murakami, S; Omagari, K; Tanaka, Y; Watanabe, T, 2015) |
| "Long-term usage of lamivudine in the treatment of chronic hepatitis B virus (HBV) infection induces the emergence of drug resistance." | ( Li, P; Lil, K; Liu, B; Pan, Y; Pu, W; Sun, A; Zhang, J; Zhang, R; Zhou, C, 2015) |
| "Lamivudine is an antiviral used for the treatment of chronic hepatitis B." | ( Calica Utku, A; Karabay, O, 2016) |
| "The goal of oral antiviral treatment for chronic hepatitis B (CHB) is to achieve and maintain undetectable HBV DNA levels." | ( Berg, T; Caruntu, FA; Elkhashab, M; Fabri, M; Flaherty, JF; Fung, S; Gane, E; Gurel, S; Hann, HW; Horban, A; Husa, P; Jablkowski, MS; Kim, K; Kitrinos, KM; Kwan, P; Massetto, B; McHutchison, JG; Pelemis, M; Sporea, I; Subramanian, GM; Yee, LJ; Yurdaydin, C, 2017) |
| "A major hurdle in the long-term treatment of chronic hepatitis B (CHB) patients is to maintain viral suppression in the absence of drug resistance." | ( Buti, M; Cathcart, AL; Corsa, AC; Flaherty, JF; Gane, EJ; Kitrinos, KM; Liu, Y; Marcellin, P; Miller, MD, 2017) |
| "One thousand and nine treatment-naïve chronic hepatitis B (CHB) patients were evaluated for cumulative rates of virologic response, biochemical response, and entecavir mutations." | ( Cho, JY; Choi, MS; Gwak, GY; Koh, KC; Lee, JH; Paik, SW; Paik, YH; Sinn, DH; Sohn, W; Yoo, BC, 2017) |
| "A retrospective cohort of 875 treatment-naive chronic hepatitis B virus (HBV) monoinfected patients (mean age 47." | ( Choi, MS; Gwak, GY; Kang, W; Kim, JH; Koh, KC; Lee, JH; Paik, SW; Paik, YH; Sinn, DH, 2017) |
| "Current treatments for chronic hepatitis B (CHB) include pegylated interferon alpha (PEG-IFN-α) which is an immune modulator, and nucleos(t)ide analogs (NAs) which directly inhibit HBV DNA polymerase." | ( Guo, H; Jiao, J; Liu, Z; Qi, W; Wang, J; Wang, X; Xu, Y; Yu, F; Zhao, P; Zhou, C, 2017) |
| "New therapies to treat chronic hepatitis B (CHB) are urgently needed." | ( Barry, V; Daffis, S; Delaney, WE; Fletcher, SP; French, DM; Huntzicker, E; Lanford, RE; Li, L; Mikaelian, I; Niu, C, 2018) |
| "Long-term treatment of chronic hepatitis B (CHB) with nucleos(t)ide analogues is often necessary to achieve durable viral suppression." | ( Buti, M; Esteban, R; Riveiro-Barciela, M, 2018) |
| "This retrospective study included treatment-naïve chronic hepatitis B patients who received at least 2 years of consecutive entecavir treatment." | ( Chang, TT; Chen, CY; Cheng, PN; Chiu, HC; Chiu, YC; Lin, TC; Liu, WC; Wu, IC, 2018) |
| "She had initially been treated for chronic hepatitis B infection with lamivudine and tenofovir, complicated by portal hypertension and variceal bleeding that thrice required banding." | ( Lelei-Mailu, FJ; Mariara, CM, 2018) |
| "Entecavir (ETV) is commonly used to treat chronic hepatitis B (CHB) in China." | ( Li, XX; Liu, XZ; Ren, GJ; Sun, D; Xu, HC; Ye, H; Zhuang, YL, 2018) |
| "It is unclear whether drugs used to treat chronic hepatitis B virus (HBV) infection cause significant renal impairment." | ( Chang, ET; Cheung, R; Chung, M; Henry, L; Hoang, J; Jeong, D; Le, AK; Lee, MH; Nguyen, MH; Trinh, S; Wang, U, 2019) |
| "The use of lamivudine for the treatment of chronic hepatitis B (CHB) is limited by high rates of lamivudine resistance." | ( Berg, T; Brodzinski, A; Fülöp, B; Jung, MC; Koukoulioti, E; Mihm, U; Sarrazin, C; Schlosser, B; Schott, E; van Bömmel, F, 2019) |
| "One strategy to treat chronic hepatitis B virus (HBV) infection could be to increase the functions of virus-specific T cells." | ( Acerbi, G; Ahn, SH; Alfieri, A; Andreone, P; Barili, V; Boni, C; Brillo, F; Brunetto, MR; Cavallone, D; Coco, B; Cursaro, C; Ferrari, C; Fisicaro, P; Fung, S; Gaggar, A; Janssen, HLA; Joshi, A; Laccabue, D; Lau, AH; Ma, X; Mangia, A; Margotti, M; Massetto, B; Pedrazzi, G; Piazzolla, V; Rodell, TC; Rossi, M; Santoro, R; Subramanian, GM; Trinh, H; Vecchi, A; Woo, J; Yoon, SK; Yoshida, EM; Zhao, Y, 2019) |
| "Antiviral treatment for chronic hepatitis B (CHB) is largely unavailable in sub-Saharan Africa; hence, little is known about the prognosis after initiating treatment in African CHB patients." | ( Aberra, H; Berhe, N; Desalegn, H; Gundersen, SG; Johannessen, A; Medhin, G; Mekasha, B, 2019) |
| "The aim of the treatment in chronic hepatitis B is to prevent progression to cirrhosis and liver cancer." | ( Aydın, N; Kırdar, S; Sayan, M; Yaşa, MH, 2019) |
| "We enrolled treatment-naïve chronic hepatitis B (CHB) and HBV-related liver cirrhosis (LC) patients treated with ETV for 24 months." | ( Cheng, LS; Jiang, W; Li, J; Liu, Y; She, WM; Shen, Y; Wang, SQ; Wu, SD, 2021) |
| "He had a history of untreated chronic hepatitis B virus infection for >29 years and no other underlying diseases." | ( Li, Q; Zhu, H, 2021) |
| "Current clinical guidelines recommend treating chronic hepatitis B virus (HBV) infection in a minority of cases, but there are relatively scarce data on evolution or progression of liver inflammation and fibrosis in cases of chronic HBV (CHB) that do not meet treatment criteria." | ( Barnes, E; Campbell, C; Collier, J; Cripps, S; Davies, J; Freeman, O; Jeffery, K; Matthews, PC; McNaughton, AL; Mokaya, J; Noble, T; Salih, H; Smith, DA; Várnai, KA; Wang, T; Woods, K, 2021) |
| "The treatment evidence for entecavir-treated chronic hepatitis B (CHB) patients without maintaining of virologic response (MVR, defined as persistent HBV DNA <20 IU/mL during therapy) remains uncertain." | ( Chen, Y; Cheng, K; Duan, X; Duan, Z; Liao, W; Lu, Y; Wang, L; Wang, X; Wang, Y; Xu, M, 2021) |
| "Tenofovir is wildly used to treat chronic hepatitis B (CHB) infection due to good potency and high genetic barrier to drug resistance." | ( Cen, S; Gu, J; Liu, T; Sun, Q; Zhang, Q, 2022) |
| "In sub-Saharan Africa, less than 1% of treatment-eligible chronic hepatitis B (CHB) patients receive antiviral therapy." | ( Aberra, H; Berhe, N; Desalegn, H; Grude, S; Gundersen, SG; Hommersand, K; Johannessen, A; Mamo, E; Orlien, SMS, 2023) |